Item 9 Labs Corp. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q3 FY2023 As of Jun 30, 2023	Q2 FY2023 As of Mar 31, 2023	Q1 FY2023 As of Dec 31, 2022	Q4 FY2022 As of Sep 30, 2022	Q3 FY2022 As of Jun 30, 2022	Q2 FY2022 As of Mar 31, 2022	Q1 FY2022 As of Dec 31, 2021	Q4 FY2021 As of Sep 30, 2021	Q3 FY2021 As of Jun 30, 2021	Q2 FY2021 As of Mar 31, 2021	Q1 FY2021 As of Dec 31, 2020	Q4 FY2020 As of Sep 30, 2020	Q3 FY2020 As of Jun 30, 2020	Q2 FY2020 As of Mar 31, 2020	Q1 FY2020 As of Dec 31, 2019	Q4 FY2019 As of Sep 30, 2019	Q3 FY2019 As of Jun 30, 2019	Q3 FY2016 As of Aug 1, 2016	Q2 FY2016 As of Mar 31, 2016	Q1 FY2016 As of Dec 31, 2015
ASSETS
Current Assets:
Cash and cash equivalents
Restricted cash and cash equivalents
Accounts receivable, net
Deferred costs
Receivable for sale of Airware assets
Inventory
Prepaid expenses
Prepaid expenses and other current assets
Total current assets

Property and equipment, net
Right of use asset
Investment in Health Defense, LLC
Deferred commissions
Construction escrow deposits
Deposits
Receivable for sale of Airware assets, net
Notes and interest receivable, net
Other assets
Assets held for sale
Intangible assets, net
Goodwill
Total Assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable
Accrued interest - related parties
Accrued payroll and payroll taxes
Accrued compensated absences
Accrued interest
Accrued expenses
Deferred revenue, current portion
Notes payable, current portion, net of discounts
Short term notes payable, net of discount
Long term debt, in default
Income tax payable
Operating lease liability, current portion
Convertible notes payable, net of discounts
Convertible notes payable to related parties - current portion
Liabilities related to assets held for sale
Total current liabilities
Convertible notes payable to related parties, less current portion, net of unamortized debt discount of $149,481 and $0 at June 30, 2016 and September 30, 2015, respectively
Long term debt

Deferred revenue, net of current portion
Operating lease liability, net of current portion
Convertible notes payable, net of current portion and discounts
Notes payables, net of current portion and discounts
Total liabilities
Stockholders' Equity:
Common stock, par value $.0001 per share, 2,000,000,000 shares authorized; 114,662,271 and 109,950,509 shares issued and 102,362,271 and 97,650,509 shares outstanding at June 30, 2023 and September 30, 2022
Common stock to be issued, 133,916 and 290,000 shares at June 30, 2016 and September 30, 2015, respectively
Additional paid-in capital
Accumulated deficit
Total Item 9 Labs Corp. stockholders' equity
Treasury stock

Total Item 9 Labs Corp. Stockholders' Equity
Non-controlling interest
Total Stockholders' Equity
Total Liabilities and Stockholders' Equity

Comments